Jim Cramer Says “CRISPR (CRSP) Keeps Losing Money Like Moderna” – Here’s Why
Jim Cramer, the host of Mad Money, reflected on the uncertainty surrounding the year 2025, focusing on several macroeconomic ...
Next-generation gene-editing tool offers enhanced capabilities for cancer and medical research
Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...
Hosted on MSN19h
CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors
CRISPR Therapeutics AG (CRSP) closed at $41.21 in the latest trading session, marking a -1.44% move from the prior day. The stock trailed the S&P 500, which registered a daily loss of 0.47%. Meanwhile ...
After inversion by CRISPR/Cas, the epigenetic state of plant chromosomes remains stable
The epigenetic state of chromatin, gene activity, and chromosomal positions are interrelated. A research team from the IPK ...